Gallium

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting

Retrieved on: 
Tuesday, May 24, 2022
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Education, Disease, History, Biopharmaceutical, Neoplasm, Annual general meeting, Research, Professor, Tams, Kupffer cell, Poster, Goal, Technetium-99m, Health, Coronavirus, Molecular imaging, Review, Decision-making, Liver, Macrophage, A Call for Unity, Mouse, PDT, Securities Act of 1933, Securities Exchange Act of 1934, NYSE American, Society of Nuclear Medicine and Molecular Imaging, Forward-looking statement, SNMMI, University, Drug Quality and Security Act, Technology, Risk, Economic development, SEC, UAB, University of Alabama System, Gallium, NYSE, Annual report, Nuclear medicine, Medical imaging, Radiology

The presentation will take place Saturday, June 11, from 6 pm 8 pm PDT (abstract ID 197; program ID 2862).

Key Points: 
  • The presentation will take place Saturday, June 11, from 6 pm 8 pm PDT (abstract ID 197; program ID 2862).
  • The abstract will be accessible on the SNMMIs Annual Meeting website prior to the meeting ( https://am.snmmi.org/iMIS/SNMMI-AM ).
  • The new imaging agents were labeled with gallium-68 (68Ga) to enable positron emission tomography (PET) imaging.
  • The ultimate goals are to develop next generation Manocept imaging agents that offer improved on-target localization and reduced off-target localization.

The Worldwide E-scrap Recycling Industry is Expected to Reach $8 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 20, 2022
Technology, Hardware, Environment, Consumer Electronics, EPA, Soil, Tubing (recreation), First Nations in Ontario, Lead, United Nations Economic and Social Commission for Asia and the Pacific, Environment, Gold, Metal, Platinum, Government, ESCAP, Geography, COVID-19, Supermarket, Element, APAC, Silver, Transport, Palladium, United Nations Economic Commission for Europe, Gallium, Industry, Time, CRT, Glass, Indium, CAGR, Growth, United Nations, Recycling, Lists of countries and territories

According to this report the e-scrap recycling market is expected to reach US$ 8,199.04 million by 2028, registering a CAGR of 14.3% from 2021 to 2028.

Key Points: 
  • According to this report the e-scrap recycling market is expected to reach US$ 8,199.04 million by 2028, registering a CAGR of 14.3% from 2021 to 2028.
  • Rigorous rules governing safe disposal and e-scrap recycling management are driving the e-scrap recycling market.
  • Such initiatives are expected to increase the demand for e-waste recycling, thereby providing lucrative opportunities to the e-scrape recycling market players across the region.
  • The e-scrap recycling market, by processed material, is segmented into metal, glass, plastic, and others.

Gallium Semiconductor Celebrates the Grand Opening of its Nijmegen R&D Center

Retrieved on: 
Wednesday, May 18, 2022
Technology, Semiconductor, Telecommunications, Gallium nitride, Engineering, R, RF, Gallium, Technology, Heart, Growth, CEO, Aluminium, Medical imaging, Operation

Gallium Semiconductor is pleased to announce the grand opening of its European R&D center in a ceremony at Kerkenbos 1224 in Nijmegen.

Key Points: 
  • Gallium Semiconductor is pleased to announce the grand opening of its European R&D center in a ceremony at Kerkenbos 1224 in Nijmegen.
  • Gallium Semi welcomed many of its valued customers, partners and vendors from the Europe region to dedicate the R&D center.
  • Nijmegen was an obvious choice for Gallium Semis new European R&D center, said Kin Tan, CEO of Gallium Semi.
  • The Nijmegen office is a fitting home for Gallium Semis European engineers designing and developing RF semiconductor solutions to support 5G and beyond networks.

POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-α Targeted Clinical Program

Retrieved on: 
Monday, May 16, 2022
Cancer, Becquerel, Risk, CEO, MTD, Gallium, Radiation, Annual general meeting, Private Securities Litigation Reform Act, Letter, Abstract, Patient, Poster, NASDAQ, AACR, HEK, MCRPC, Clinical trial, Association, COVID-19, Radioligand, Intention, Dosimetry, FAP, Index (publishing), American Association for Cancer Research, Prostate cancer, Program, Terminology, Forward-looking statement, Tolerability, Heterotrimeric G protein, SPLASH, Therapy, Health Canada, Safety, American Association, Isotope, Radiopharmaceutical, SEC, Prevalence, GLOBE, Actinium-225, Melanoma, Molecular imaging, Medical imaging, Pharmaceutical industry

INDIANAPOLIS, May 16, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced details of the initial clinical trial in the Company’s pan-cancer Fibroblast Activation Protein-α (FAP-α) targeted program PNT2004, FRONTIER.

Key Points: 
  • The Phase 1 clinical protocol will evaluate PNT6555 in ~30 patients in five FAP-avid cancer indications: colorectal, pancreatic, esophageal, melanoma, and soft tissue sarcoma.
  • We believe radiopharmaceuticals are on the verge of a revolution, said Dr. Joe McCann, CEO of POINT Biopharma.
  • About POINT Biopharma Global Inc.
    POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer.
  • Information about POINT Biopharma Global Inc.s Phase 3 SPLASH trial for metastatic castrate resistant prostate cancer (mCRPC) patients can be found at https://www.splashtrial.com/ .

Monrol Is Partnering With Telix Pharmaceuticals, Supplying Lutetium nca Lu 177 for the Manufacturing of Clinical Doses for the Phase II STARLITE 2 Study At MSK and Manufacturing Clinical Doses for Telix’s Phase III ZIRCON Trial

Retrieved on: 
Tuesday, May 10, 2022
Science, Other Science, Pharmaceutical, Medical Supplies, Oncology, Health, Hospitals, Clinical Trials, TGA, Safety, Radionuclide, Nivolumab, Degenerative disease, Gallium, CDMO, Carbonic anhydrase, Positron emission tomography, Quality of life, Radiopharmaceutical, Technology, Nuclear medicine, Transport, CFR, ASX, PRRT, Phase, Australian Securities Exchange, Kidney cancer, Oncology, MRI, Patient, NET, Clinical trial, Lung, CA9, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MTR, Breakthrough therapy, LinkedIn, Prostate, Neoplasm, Title 21 CFR Part 11, Histology, Bristol Myers Squibb, PET/CT, Memorial Sloan Kettering Cancer Center, GMP, Movement, Cancer, MSK, Food, Radiation, CT, Diagnosis, Kidney, Prostate cancer, PET, Pharmaceutical industry, Vaccine, Medical imaging, Tax advisor, Animal, Telix, Lutetium

Monrol supplied Lutetium (Lu-177 n.c.a) to Telix Pharmaceuticals to manufacture clinical doses of TLX250 for STARLITE 2 Phase II study.

Key Points: 
  • Monrol supplied Lutetium (Lu-177 n.c.a) to Telix Pharmaceuticals to manufacture clinical doses of TLX250 for STARLITE 2 Phase II study.
  • Clinical doses of Telixs investigational renal cancer companion imaging agent TLX250-CDx (89Zr-DFO-girentuximab) is also produced by Eczacbas Monrol in its Istanbul facility for the Phase III ZIRCON clinical trial.
  • ZIRCON Phase III study (Zirconium Imaging in Renal Cancer Oncology) is an international multi-centre study at 34 sites in Europe, Australia, Turkey, Canada, and the United States.
  • Telixs companion investigational diagnostic imaging agent TLX250-CDx (89Zr-DFO-girentuximab) is the subject of a global Phase III trial recruiting (ZIRCON trial, NCT03849118 ).

VCSEL Market Worth $5.76 Billion by 2029 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®

Retrieved on: 
Thursday, May 5, 2022
VR, Gallium nitride, Gallium arsenide, Fourth Industrial Revolution, Ams AG, Geography, Smartglasses, Electron, Aluminium gallium arsenide, Augmented reality, Adoption, Technology, Longevity, Health, Infection, IQE, Industry, Broadcom Inc., Telecommunications network, Leonardo S.p.A., Semiconductor, Investment, Gallium, RF, Facial recognition, Entertainment, Lidar, Efficiency, Home Building Association Bank, CAGR, Growth, 3D, COVID-19, II-VI Incorporated, National Security Surveillance Act, Teledyne Technologies, Electronics, Light-emitting diode, Quarantine, Tablet, TT Electronics, ROF, Virtual reality, Impact, AR, Aluminium, Video game console, 3D printing, VCSEL, Indium phosphide

Increasing use of VCSEL in 3D sensing applications and VCSEL arrays by data centers are the major factors driving the growth of the VCSEL market.

Key Points: 
  • Increasing use of VCSEL in 3D sensing applications and VCSEL arrays by data centers are the major factors driving the growth of the VCSEL market.
  • Based on type, the VCSEL market is segmented into multi-mode VCSEL and single-mode VCSEL.
  • The multi-mode VCSEL segment is expected to account for the larger share of the VCSEL market in 2022.
  • Smartphones being the major application area for VCSEL, the market in Asia-Pacific is bound to grow exponentially over the forecast period.

VCSEL Market Worth $5.76 Billion by 2029 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®

Retrieved on: 
Thursday, May 5, 2022
VR, Gallium nitride, Gallium arsenide, Fourth Industrial Revolution, Ams AG, Geography, Smartglasses, Electron, Aluminium gallium arsenide, Augmented reality, Adoption, Technology, Longevity, Health, Infection, IQE, Industry, Broadcom Inc., Telecommunications network, Leonardo S.p.A., Semiconductor, Investment, Gallium, RF, Facial recognition, Entertainment, Lidar, Efficiency, Home Building Association Bank, CAGR, Growth, 3D, COVID-19, II-VI Incorporated, National Security Surveillance Act, Teledyne Technologies, Electronics, Light-emitting diode, Quarantine, Tablet, TT Electronics, ROF, Virtual reality, Impact, AR, Aluminium, Video game console, 3D printing, VCSEL, Indium phosphide

Increasing use of VCSEL in 3D sensing applications and VCSEL arrays by data centers are the major factors driving the growth of the VCSEL market.

Key Points: 
  • Increasing use of VCSEL in 3D sensing applications and VCSEL arrays by data centers are the major factors driving the growth of the VCSEL market.
  • Based on type, the VCSEL market is segmented into multi-mode VCSEL and single-mode VCSEL.
  • The multi-mode VCSEL segment is expected to account for the larger share of the VCSEL market in 2022.
  • Smartphones being the major application area for VCSEL, the market in Asia-Pacific is bound to grow exponentially over the forecast period.

Gallium Oxide in Semiconductors Market Report to 2030 - Increasing Demand for Gallium Oxide Transistors is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 28, 2022
Technology, Natural Resources, Semiconductor, Mining, Minerals, Gallium, Alkali, Associated Chamber Music Players, Wind, Water, Electronics, Gallium oxide, Power semiconductor device, RF, Efficiency, Growth, USGS, Epitaxial wafer, Mergers & Acquisitions, Product, MOSFET, Car, Aluminum Corporation of China Limited, CAGR, EY, View, Research, Electricity, Commerce, Industry, ASSOCHAM, EV, Aircraft, FET amplifier, Semiconductor, Aluminium, Electronic component, Semiconductor, SAARC

The chemical's high efficiency is expected to help the global gallium oxide in semiconductor market expansion.

Key Points: 
  • The chemical's high efficiency is expected to help the global gallium oxide in semiconductor market expansion.
  • The report covers an in-depth analysis of the following segments of the Gallium Oxide in Semiconductor Market.
  • By Product - (3N) 99.9% Gallium Oxide, (4N) 99.99% Gallium Oxide, (5N) 99.999% Gallium Oxide and (6N) 99.9999% Gallium Oxide.
  • Product Launches, Merger & Acquisition, joint ventures and R&D activities are key strategies adopted by the players in Gallium Oxide in Semiconductor Market.

Global VCSEL Markets Report 2022-2029: Growing Application of VCSELs in Vehicle Automation & Increasing Use of VCSELs in 5G Technology

Retrieved on: 
Monday, April 25, 2022
Aluminium gallium arsenide, Health, Lidar, Gallium arsenide, Adoption, VCSEL, Telecom Regulatory Authority of India, CAGR, Growth, Electronics, Gallium nitride, Home Building Association Bank, AGC Aerospace & Defense, Industry, Fourth Industrial Revolution, Investment, Multimedia, Gallium, Aluminium, Indium phosphide, Geography

The VCSELs market is expected to reach $5.76 billion by 2029, at a CAGR of 26.5% during the forecast period, 2022-2029.

Key Points: 
  • The VCSELs market is expected to reach $5.76 billion by 2029, at a CAGR of 26.5% during the forecast period, 2022-2029.
  • The growing application of VCSELs in vehicle automation and the increasing use of VCSELs in 5G technology are expected to create growth opportunities for the players operating in the VCSELs market.
  • Based on type, the VCSELs market is segmented into multi-mode VCSELs and single-mode VCSELs.
  • Smartphones being the major application area for VCSELs, the market in Asia-Pacific is bound to grow exponentially over the forecast period.

Telix Further Strengthens European Distribution Network for Illuccix

Retrieved on: 
Friday, April 22, 2022
Gallium, Degenerative disease, ASX, Diagnosis, European Association of Urology, LinkedIn, LDA, Neurology, TGA, Nuclear medicine, FDA, Kit, EMEA, EAU, Food, Radiopharmaceutical, Company, Solution, Man, Oncology, PET, PSMA, Australian Securities Exchange, Goal, IRE, Prostate cancer, THP, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Radiology, MTR, TLX, Animal, Medical imaging, Pharmaceutical industry, Urology, Avanos Medical, Telix

Under the terms of the new agreement, THP will be the exclusive commercial distributor of Illuccix for a period of five years from national approval.

Key Points: 
  • Under the terms of the new agreement, THP will be the exclusive commercial distributor of Illuccix for a period of five years from national approval.
  • [1]
    Telix CEO EMEA, Richard Valeix added, "Telix is building an extensive distribution network across Europe, with high quality partners with a strong reputation and radiopharmaceutical experience.
  • Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases.
  • [5] Telix is also progressing marketing authorisation applications for this investigational candidate in Europe[6] and Canada.